Bio-Rad Laboratories, Inc. (BIO) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Clinical Diagnostics Segment Revenue (Net Sales) | 363.8M | FY2026-Q1 |
| Free Cash Flow (Non-GAAP) | 78.05M | FY2026-Q1 |
| Gross Margin (Non-GAAP) | 53.10 percent | FY2026-Q1 |
| Life Science Segment Revenue (Net Sales) | 228.75M | FY2026-Q1 |
| Operating Margin (Non-GAAP) | 6.60 percent | FY2026-Q1 |
| Clinical Diagnostics Revenue Mix | 61.00 percent | FY2026-Q1 |
| Life Science Revenue Mix | 39.00 percent | FY2026-Q1 |
Back to BIO overview · BIO earnings · BIO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.